All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Sun Pharma Announces FDA Approval of Next Generation BLU-U Blue Light Photodynamic Therapy Illuminator for Actinic Keratosis
The BLU-U Model 4170E offers a compact, easy-to-use option with the same BLU-U safety and efficacy healthcare professionals have trusted for years.
AGC Biologics, Quell Therapeutics partner to advance Treg cell therapies
Under the partnership, AGC Biologics will supply lentiviral vector (LVV) material through its ProntoLVV platform and Quell its expertise in advanced treatments for immune and inflammatory disorders
Amneal gets FDA approval for Brekiya to treat migraine and cluster headaches
Brekiya provides a convenient, ready-to-use solution that does not require refrigeration, assembly, or priming, and the autoinjector is set to be launched in the latter half of 2025.
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
This financing marks a major milestone for Pathos as it expands its AI-enabled platform to drive greater speed, precision, and success in oncology drug development.
Merck secures FDA approval for Welireg to treat advanced PPGL
Welireg is an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, indicated for adults and children aged 12 and older with advanced pheochromocytoma or paraganglioma (PPGL).
Novo Nordisk, Septerna enter $2.2bn collaboration for GPCR therapies
The partnership will leverage Novo Nordisk’s expertise in cardiometabolic conditions and Septerna’s proficiency in G protein-coupled receptor (GPCR) drug discovery.
Tempus Enters Multi-Year Strategic Collaboration with Boehringer Ingelheim to Advance its Cancer Pipeline
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare
AstraZeneca secures UK’s MHRA approval for Trixeo Aerosphere
Trixeo Aerosphere is a fixed-dose triple-combination inhaler medication that combines budesonide, glycopyrronium, and formoterol fumarate, and is approved for use with a new propellant, HFO-1234ze(E)
Biodexa secures EC orphan drug designation for eRapa in FAP
eRapa is an oral tablet formulation of rapamycin, an mTOR inhibitor involved in cellular metabolism and growth regulation that targets FAP, a precancerous colon condition lacking pharmaceutical interventions.
Lilly, Purdue University expand collaboration with investment up to $250m
The Lilly-Purdue 360 initiative aims to advance pharmaceutical innovation across the entire drug development pipeline, one of the largest industry-academic partnerships in the US.